The Osteoarthritis Research Society International (OARSI) submitted a white paper on December 1, 2016 asking the Federal Drug Administration (FDA) to consider OA as a serious disease. As an organization of professionals dedicated to the study of OA, OARSI is concerned about the growing population of OA patients, many of whom may experience progressive disability and decreased quality of life.

Read more